Catalent vs Piramal Pharma Solutions: CDMO Comparison
How does Catalent compare to Piramal Pharma Solutions for ADC manufacturing?
Side-by-side comparison of Catalent and Piramal Pharma Solutions on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Catalent has more FDA inspections on record (12 vs 5) — a deeper regulatory paper trail.
- Piramal Pharma Solutions carries a cleaner inspection mix — no OAI classifications versus 2 for Catalent.
- Catalent has 2 FDA warning letters on record; Piramal Pharma Solutions has none.
- Catalent has materially broader EMA GMP coverage (19 active certificates vs 1) — stronger EU footprint.
On a 13-modality CDMO landscape, both Catalent and Piramal Pharma Solutions qualify as ADC manufacturers; Piramal Pharma Solutions carries the higher composite Signal Score for ADC programs in this comparison.
What to evaluate for ADC programs
Both Catalent and Piramal Pharma Solutions qualify as ADC CDMOs. When choosing between them for ADC programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
HPAPI containment
Look for OEB-5 (sub-microgram occupational exposure band) suites for handling cytotoxic payloads end-to-end. Containment maturity is the floor for credible commercial ADC work.
Linker-payload chemistry on file
Match the CDMO's payload + linker experience to your program. MMAE / vc-MMAE is the most common; PBDs, calicheamicin, Dxd-class topoI inhibitors, and TLR agonists each carry distinct handling and analytical demands.
Commercial bioconjugation track record
Has the CDMO conjugated a commercially-approved ADC? Track record on Polivy, Padcev, Trodelvy, Enhertu, Tivdak, Elahere, Adcetris, Mylotarg, Besponsa, Lumoxiti, Blenrep, etc. is a strong qualifying signal.
Integrated DS + DP
Bioconjugation produces ADC drug substance; you'll also need sterile fill-finish for drug product. Confirm whether the CDMO covers both or partners — both routes work, but integrated is faster on transfer.
Frequently asked: Catalent vs Piramal Pharma Solutions
How does Catalent compare to Piramal Pharma Solutions for ADC manufacturing?
On CDMO Signal's composite Signal Score, Catalent is 76/100 and Piramal Pharma Solutions is 84/100; Catalent has 12 FDA inspections on record vs 5 for Piramal Pharma Solutions; European coverage is 35 active EMA+MHRA certificates for Catalent vs 13 for Piramal Pharma Solutions. Both are tracked in the CDMO Signal directory as ADC CDMOs. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.
Which has the stronger FDA inspection record, Catalent or Piramal Pharma Solutions?
Catalent has 12 FDA inspections on record (NAI 3 / VAI 7 / OAI 2) and 2 warning letters. Piramal Pharma Solutions has 5 FDA inspections on record (NAI 1 / VAI 4 / OAI 0) and 0 warning letters.
How do Catalent and Piramal Pharma Solutions compare on European GMP coverage?
Catalent holds 19 active EMA GMP certificates and 16 MHRA / UK certificates. Piramal Pharma Solutions holds 1 active EMA GMP certificate and 12 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is better for ADC manufacturing — Catalent or Piramal Pharma Solutions?
Both Catalent and Piramal Pharma Solutions are tagged as ADC CDMOs in our directory, so both are credible options for ADC programs. The most important differentiator for ADC selection is typically hpapi containment: Look for OEB-5 (sub-microgram occupational exposure band) suites for handling cytotoxic payloads end-to-end. Containment maturity is the floor for credible commercial ADC work. Review each CDMO's profile and inspection record before shortlisting.
What does the Signal Score gap mean in practice?
Catalent carries a Signal Score of 76/100 and Piramal Pharma Solutions carries 84/100 — a small lead for Piramal Pharma Solutions. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →